Viatris (VTRS) Net Equity Issued and Repurchased (2022 - 2026)

Viatris' (VTRS) quarterly Net Equity Issued and Repurchased came in at $500000.0 in Q1 2026, down 16.67% year-on-year from $600000.0 in Q1 2025, and down 16.67% quarter-over-quarter from $600000.0 in Q4 2025.

Viatris (VTRS) Net Equity Issued and Repurchased (2022 - 2026) Analysis & Trends

Viatris' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $500000.0 for Q1 2026.

  • On a quarterly basis, Net Equity Issued and Repurchased fell 16.67% year-over-year to $500000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.6 million, up 4.0% from the prior year.
  • Net Equity Issued and Repurchased eased to $500000.0 in Q1 2026 per VTRS's latest filing, from $600000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $1.8 million in Q3 2022 and bottomed at $500000.0 in Q1 2026.
  • The 5-year median for Net Equity Issued and Repurchased is $700000.0 (2022), against an average of $750000.0.
  • Across the five-year window, Net Equity Issued and Repurchased sank 55.56% in 2023 and climbed 16.67% in 2025, its largest moves.
  • Year by year, Net Equity Issued and Repurchased stood at $800000.0 in 2022, then decreased by 25.0% to $600000.0 in 2023, then changed by 0.0% to $600000.0 in 2024, then changed by 0.0% to $600000.0 in 2025, then retreated by 16.67% to $500000.0 in 2026.
  • Per Business Quant, the three latest VTRS Net Equity Issued and Repurchased figures stand at $500000.0 (Q1 2026), $600000.0 (Q4 2025), and $700000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn -
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn -
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 500,000.00
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 23.60 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn -
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 500,000.00
Mar 31, 2026 500,000.00
Dec 31, 2025 600,000.00
Dec 31, 2025 600,000.00
Sep 30, 2025 700,000.00
Sep 30, 2025 700,000.00
Jun 30, 2025 700,000.00
Jun 30, 2025 700,000.00
Mar 31, 2025 600,000.00
Mar 31, 2025 600,000.00
Dec 31, 2024 600,000.00
Dec 31, 2024 600,000.00
Sep 30, 2024 600,000.00
Sep 30, 2024 600,000.00
Jun 30, 2024 700,000.00
Jun 30, 2024 700,000.00
Mar 31, 2024 600,000.00
Mar 31, 2024 600,000.00
Dec 31, 2023 600,000.00
Dec 31, 2023 600,000.00